The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.

Bruce F BeboInna CintinaNicholas LaRoccaLeslie RitterBari TalenteDaniel HartungSurachat NgorsurachesMitchell T WallinGrace Yang

Published in: Neurology (2022)

MS is a costly chronic disease, with direct costs of prescription drugs and indirect productivity loss being important cost drivers. Our findings suggested that the burden of MS in the United States has been underestimated.

Keyphrases

multiple sclerosis
mass spectrometry
ms ms
white matter
climate change